THALES
Eseye, a global IoT connectivity solutions provider, has selected Thales to accelerate and simplify worldwide IoT deployment with a seamless connectivity solution. Thales pioneering solution enables Eseye to automatically connect IoT devices with the most appropriate profile the first time they are powered up and in-life. Thales Adaptive Connect (TAC) based on eSIM (embedded SIM) technology that drastically simplifies the management of IoT devices lifecycle. It is the first market-ready solution that eliminates the need to configure mobile subscriptions in the factory, or for technicians to visit them in the field.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228389495/en/
@Thales
Eseye provides IoT cellular connectivity services worldwide, and TAC brings connectivity management of IoT devices remotely to make it far easier for its customers to roll-out and support major projects in areas such as: smart utilities, supply chains, logistics, and automotive. Indeed, any kind of IoT device can be deployed and connected in any region or country without being configured beforehand.
TAC is remotely managing the eSIM automatic configuration to provide the best local connectivity from its first usage and throughout its lifespan on the field. With Thales, Eseye can ensure they all connect to the preferred mobile network whenever it is needed. For example, deployed IoT devices can be switched to another mobile network remotely, over-the-air, at any time. The Thales solution fully complies with GSMA eSIM IoT standard SGP.32, ensuring security, reliability, and future proof capability for massive IoT use cases.
Thanks to the Thales connectivity offer for eSIM-based devices, Eseye will be able to operate and manage flexible, end-to-end connectivity from the factory to the field, and throughout the device lifecycle. Which means the entire operation, including manufacturing, logistics, and connectivity, is streamlined and simplified.
“Eseye are delighted to be partnering with Thales to take forward this leading-edge, innovative new IoT solution. Combining SGP.32 and SGP.41 support will ensure future IoT device deployments can deliver optimum efficiency and value to our customers. Not only do Enterprise customers get a completely future proofed eSIM platform, but it also enables maximum choice of either personalising devices for local mobile networks ahead of deployment or using TAC to do this for them in the field” said Adam Hayes, Chief Operating Officer at Eseye.
"Eseye is a dynamic partner with whom we have also worked on a Proof of Concept for customers interested in in-factory provisioning (IFPP) for their devices. This enables profiles to be securely provisioned during the device manufacturing process. For example, a blood sugar monitor device that has been configured at the factory will have a substantially longer battery life since there is no need for an in-field local profile download. This solution, which meets the latest market specifications (SGP.41), retains all of the benefits of an automatic and cost-effective connection to the preferred local network," said Guillaume Lafaix, VP of Connectivity Solutions and Embedded Products at Thales.
About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive. The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity. Thales has 77,000[1] employees in 68 countries. In 2022, the Group generated sales of €17.6 billion. [1] Excluding the Transport business |
PLEASE VISIT
Thales Group
Digital Identity & Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228389495/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release
Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli
Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press release
Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately up to 40 million people in the European Union (EU)1-4 Prurigo nodularis is a serious skin disease characterized by chronic itch, skin nodules covering large body areas, and poor sleep quality, which is estimated to affect up to 111 people per 100,000 in the EU5-10 Nemolizumab is a first-in-class monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and skin barrier dysfunction in both atopic dermatitis and prurigo nodularis11-13 This positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommending the granting of marketing authorization of nemolizumab in the European Union (EU) for the treatment of both atopic dermatitis and prurigo n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom